A comparative analysis indicates SLC7A11 expression regulate the prognostic value of KEAP1-NFE2L2-CUL3 mutations in human uterine corpus endometrial carcinoma

被引:1
作者
Namani, Akhileshwar [1 ]
Veeraiyan, Durgadevi [1 ]
Patra, Tapas [1 ]
机构
[1] Sri Shankara Canc Hosp & Res Ctr, Dept Mol Res, Bangalore, India
关键词
Uterine corpus endometrial carcinoma; Progression free survival; Glutathione synthesis; The cancer genome atlas; CANCER; NRF2; RESISTANCE; THERAPY; PATHWAY; KEAP1;
D O I
10.1016/j.freeradbiomed.2024.06.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Uterine corpus endometrial cancer (UCEC) is a third most common malignancy in women with a poor prognosis in advanced stages. In this study, we performed an integrated comparative analysis of exome and transcriptome data from The Cancer Genome Atlas (TCGA) of Lung Adenocarcinoma (LUAD), and UCEC patients. Our multiomics analysis shows that the UCEC patients carrying mutations in the KEAP1-NFE2L2-CUL3 genes were associated with better progression-free survival (PFS), whereas the KEAP1-NFE2L2-CUL3 mutation in LUAD showed poor outcomes. Functional annotations and correlative expression studies show that genes, particularly GCLC and GCLM related to glutathione synthesis are expressed at lower levels in the KEAP1-NFE2L2-CUL3 mutant UCEC compared to LUAD. This events result in glutathione deficiency and it may compromise to combat intracellular reactive oxygen species (ROS). However, the expression of genes involved in the glutathione recycling process was not affected. On the other hand, cellular import of cystine is high due to increased SLC7A11 expression in UCEC. Because glutathione synthesis is impaired, the unconverted cysteine accumulates in cells, leading to di-sulfite stress. Apart from NRF2, ARID1A is one of the positive regulators of SLC7A11. In support, UCEC patients with co-occurrence of KEAP1-NFE2L2-CUL3 and ARID1A mutation shows significantly decreased PFS with decline of SLC7A11 expression as compared to patients carrying only KEAP1-NFE2L2-CUL3 mutation. Thus, we hypothesize that the KEAP1-NFE2L2-CUL3 mutation in UCEC leads to uncontrollable ROS with di-sulfite stress, reflecting a favorable clinical outcome.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 26 条
[21]   Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer [J].
Shibata, Tatsuhiro ;
Kokubu, Akiko ;
Gotoh, Masahiro ;
Ojima, Hidenori ;
Ohta, Tsutomu ;
Yamamoto, Masayuki ;
Hirohashi, Setsuo .
GASTROENTEROLOGY, 2008, 135 (04) :1358-1368
[22]   NRF2 Mutation Confers Malignant Potential and Resistance to Chemoradiation Therapy in Advanced Esophageal Squamous Cancer [J].
Shibata, Tatsuhiro ;
Kokubu, Akiko ;
Saito, Shigeru ;
Narisawa-Saito, Mako ;
Sasaki, Hiroki ;
Aoyagi, Kazuhiko ;
Yoshimatsu, Yuki ;
Tachimori, Yuji ;
Kushima, Ryoji ;
Kiyono, Tohru ;
Yamamoto, Masayuki .
NEOPLASIA, 2011, 13 (09) :864-U133
[23]   Transcriptional Regulation by Nrf2 [J].
Tonelli, Claudia ;
Chio, Iok In Christine ;
Tuveson, David A. .
ANTIOXIDANTS & REDOX SIGNALING, 2018, 29 (17) :1727-1745
[24]   SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells [J].
Yan, Yuelong ;
Teng, Hongqi ;
Hang, Qinglei ;
Kondiparthi, Lavanya ;
Lei, Guang ;
Horbath, Amber ;
Liu, Xiaoguang ;
Mao, Chao ;
Wu, Shiqi ;
Zhuang, Li ;
You, M. James ;
Poyurovsky, Masha V. ;
Ma, Li ;
Olszewski, Kellen ;
Gan, Boyi .
NATURE COMMUNICATIONS, 2023, 14 (01)
[25]   Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells [J].
Zhan, Lijuan ;
Zhang, Hao ;
Zhang, Qiang ;
Woods, Courtney G. ;
Chen, Yanyan ;
Xue, Peng ;
Dong, Jian ;
Tokar, Erik J. ;
Xu, Yuanyuan ;
Hou, Yongyong ;
Fu, Jingqi ;
Yarborough, Kathy ;
Wang, Aiping ;
Qu, Weidong ;
Waalkes, Michael P. ;
Andersen, Melvin E. ;
Pi, Jingbo .
FREE RADICAL BIOLOGY AND MEDICINE, 2012, 53 (04) :758-768
[26]   KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials [J].
Zhu, Hongyuan ;
Xie, Daipeng ;
Yu, Yunfang ;
Yao, Lintong ;
Xu, Bin ;
Huang, Luyu ;
Wu, Shaowei ;
Li, Fasheng ;
Zheng, Yating ;
Liu, Xinyi ;
Xie, Wenzhuan ;
Huang, Mengli ;
Li, Hao ;
Zheng, Shaopeng ;
Zhang, Dongkun ;
Qiao, Guibin ;
Chan, Lawrence W. C. ;
Zhou, Haiyu .
FRONTIERS IN ONCOLOGY, 2021, 11